The CTD of the largest subunit, POLR2A, of human RNAPII consists of multiple, sometimes degenerate, heptapeptide repeats with consensus sequence 1- 2) . The CTD is phosphorylated during transcription on Y1, T4 and all three serine residues 3 . Different phosphorylation patterns, proline isomerization 3,4 and modification of nonconsensus CTD residues 5 create a 'CTD code' 6 that recruits various factors to regulate transcription, mRNA processing and histone modification 5, [7] [8] [9] [10] . There also appears to be cross-talk between different CTD modifications 5 .
a r t i c l e s
The CTD of the largest subunit, POLR2A, of human RNAPII consists of multiple, sometimes degenerate, heptapeptide repeats with consensus sequence 1-YSPTSPS-7 (refs. 1,2). The CTD is phosphorylated during transcription on Y1, T4 and all three serine residues 3 . Different phosphorylation patterns, proline isomerization 3, 4 and modification of nonconsensus CTD residues 5 create a 'CTD code' 6 that recruits various factors to regulate transcription, mRNA processing and histone modification 5, [7] [8] [9] [10] . There also appears to be cross-talk between different CTD modifications 5 .
General transcription factor TFIIH phosphorylates S5 and S7 (to form S5P and S7P) in promoter regions [11] [12] [13] [14] [15] , where S5P recruits mRNA-capping enzymes [16] [17] [18] [19] , the yeast COMPASS complex for histone H3 K4 trimethylation by Set1 (MLL proteins in humans) [20] [21] [22] and the yeast Sen1-Nrd1-Nab3 complex to terminate noncoding small nuclear RNAs (snRNAs), small nucleolar RNAs and cryptic unstable transcripts 23 . S5P also characterizes 'poised' RNAPII in metazoan promoter regions [24] [25] [26] [27] . RNAPII escaping the promoter is phosphorylated on S2 by p-TEFb 28, 29 , CDK12 and/or CDK13 (ref. 30) and BRD4 (ref. 31) . Transition from high S5P to high S2P is accompanied by partial dephosphorylation of S5P by Rtr1 in yeast 32 . The human Rtr1 homolog RPAP2 is similarly needed for dephosphorylation of S5P during snRNA gene transcription 33 . Further downstream, S7P 34 and the remaining S5P 35, 36 are removed by Ssu72. S2P dephosphorylation is carried out by yeast Fcp1 and its mammalian homolog CTDP1 (refs. 28,37,38) .
Despite extensive CTD studies, how the CTD is structurally organized and how CTD modifications regulate each other remain largely unknown. In addition, the phosphatase activity of RPAP2 is controversial 33, 39 . We set out here to characterize three human CTDinteracting proteins. Our structural and biophysical studies show that the CID-containing proteins RPRD1A, RPRD2 and RPRD1B (an oncoprotein) 40 , all of which associate with RNAPII 41 , associate preferentially as dimers with S2P-and, to a lesser extent, with S7P-containing CTD peptides, whereas S5P interferes with binding. We show that RPAP2 is a substrate-selective phosphatase whose interaction with RNAPII requires RPRD1A and/or RPRD1B. By binding two S2P and/or S7P CTD repeat-containing decameric sequences, RPRD1A-RPRD1B dimers act as scaffolds that organize the CTD to present S5P located in the intervening region to RPAP2 for dephosphorylation.
RESULTS

Recognition of specific CTD phosphoisoforms by RPRDs
RPRD1A, RPRD1B and RPRD2 ('RPRDs') were previously found to coprecipitate with phosphorylated RNAPII 41 . Here we used isothermal a r t i c l e s titration calorimetry (ITC) to determine dissociation constants of recombinant RPRD CIDs (Fig. 1a) for CTD peptides containing two heptapeptide repeats without modification (UnM) or with serine phosphorylation at positions 2, 5 or 7 (S2P, S5P or S7P, respectively). The CTD binding affinities of the three RPRD CIDs followed the order S2P (K d from 6.8 to 8.4 µM) > S7P (K d from 23.6 to 82.8 µM) > UnM (K d from 114 to 355 µM) > S5P CTD (K d >1,000 µM) ( Table 1) . Combining S2P and S7P on the same repeats (denoted S2,7P CTD) increased the RPRD1A and RPRD1B affinities by 1.6-fold and 2.6-fold, respectively, compared to S2P alone, whereas the RPRD2 CID affinity remained unchanged. In contrast, S5P in the same heptapeptide repeat with either S2P or S7P (i.e., S2,5P CTD or S5,7P CTD, respectively, in Table 1 ) abolished detectable binding (K d >1,000 µM) for all three CIDs. This result and our previous observation that RPRDs coprecipitate with S5P-containing RNAPII in cell extracts 41 imply that S5P-containing repeats exist on the same CTDs as do S2-and/or S7-containing repeats that bind RPRDs. That S5P on a repeat adjacent to one with S7P (S7P-S5P CTD in Table 1 ) had no significant effect on CTD binding supports this idea.
Thirty-one of 52 mammalian CTD repeats, mainly in the C-terminal half, deviate from consensus, predominantly at position 7 and most frequently by lysine substitution. With a CTD peptide containing S2P and lysine rather than serine at position 7 (S2P-K7 CTD in Table 1 ), RPRD1A bound 8.4-fold more strongly than to a consensus peptide, whereas RPRD2 CID binding was about 1.6-fold stronger, and RPRD1B CID binding was slightly weaker (0.8-fold). These data suggest that RPRDs would bind many, if not most, nonconsensus CTD repeats.
Crystal structures of RPRD CID-CTD complexes
To better understand how RPRDs recognize the CTD, we obtained crystal structures for various RPRD CID-CTD complexes, starting with a 1.9-Å-resolution structure of the RPRD1A CID bound to a 19-mer S7P CTD peptide, SPSYSPTSPSYSPTSPSYS, containing more than two heptapeptide repeats bearing three S7P residues (underlined). Like the CIDs of its yeast homologs, Rtt103, Pcf11 and Nrd1 (refs. 23,42,43) , the RPRD1A CID contained eight α-helices arranged in a right-handed superhelical manner (Fig. 1b) . A concave channel accommodated the CTD decapeptide PSYSPTSPSY (S7P underlined) in a linear conformation such that two S7P residues, S7aP and S7bP, occupied the channel entrance and exit, respectively (Fig. 1c,d ). Structure statistics for structures described here are shown in Table 2 and Supplementary Table 1 .
We observed many CID-CTD contacts (Fig. 1c-e) . CID N18 formed water-mediated npg a r t i c l e s hydrogen bonds with the S7a phosphate group and the backbone carbonyl group of Y1b and further hydrogen bonds with the backbone amide of Y1b. N64 and D65 hydrogen-bonded to the Y1b phenolic hydroxyl group deeply buried inside the center of the channel. N64 also contacted the P3b carbonyl group via a hydrogen bond. Q20 formed hydrogen bonds with the P6a carbonyl group, the CTD backbone amide of S2b and the S5b hydroxyl group. R114 hydrogen-bonded with the carbonyl groups of both T4b and P6b. N69 formed water-mediated hydrogen bonds with both the backbone amide and phosphate group of S7b. In addition, I110 contacted both P3b and T4b through hydrophobic interactions. Finally, the two S7P phosphate groups pointed toward nearby positively charged areas of the CID surface, one of them close to R72 (Fig. 1c) . Altogether, direct and indirect hydrogen bonds, hydrophobic interactions and electrostatic forces contribute to the interaction network between the S7P CTD and the RPRD1A CID. Of note, CTD residue S5b was deeply buried in a negatively charged environment inside the channel and formed hydrogen bonds with Q20 ( Fig. 1c-e) . A phosphate group at this position would result in steric hindrance and charge repulsion, thus accounting for disruption of CTD binding by S5P. Conversely, the two S7 positions at the channel entrance and exit probably enable flexibility for S7 modification and substitution by different amino acids, thus explaining CID binding to CTD repeats with K instead of S at position 7 (8/31 nonconsensus repeats).
To address whether RPRD CIDs similarly recognize an S2P-containing CTD, we crystallized the RPRD1B CID with the 19-mer S2P CTD peptide SPSYSPTSPSYSPTSPSYS (S2P underlined) (Fig. 2a) . This 1.85-Å-resolution structure exhibited intrahomodimeric swapping of two C-terminal helices, a phenomenon known as domain swapping 44 , but the overall architecture of the CID surface was similar to the nonswapped RPRD1A CID. Thus, folding of the RPRD1B CID and contact residues between the S2P CTD peptide and the CID (Fig. 2a,b) were highly similar to those observed in the RPRD1A CID-S7P CTD complex (Fig. 1d,e) . Importantly, the highly conserved residue R106 formed two hydrogen bonds with the S2bP phosphate group, thus explaining the enhanced affinity over the unmodified CTD peptide ( Table 1 ). Other differences included N69 forming water-mediated hydrogen bonds with the S7b hydroxyl group and N18 not making contact with S7a. The domain-swapped structure is likely to be stabilized by a disulfide bond involving C100 in both RPRD1B polypeptides (Fig. 2a) . Whether the domain-swapped structure actually forms in vivo is unclear.
We also determined a 1.85-Å-resolution structure of the RPRD1B CID in complex with the 19-mer UnM CTD peptide SPSYSPTSPSYSPTSPSYS. The folding and binding mode in this structure were also similar to those of the RPRD1A-S7P CTD and RPRD1B-S2P CTD complexes, but they lacked phosphate-specific interactions and N69 interactions with the CTD (Fig. 2c,d) . Unlike the β-turn CTD conformation in complexes with Pcf11 and Rtt103 (refs. 42,43) , the decamer CTD peptides in all three RPRD CID complexes exhibited similar extended conformations (Fig. 2e,f) .
Collectively, our structures with both unmodified and phosphorylated CTD peptides showed a conserved CID-CTD interface, with phosphorylation of S2 and S7 enhancing the interactions. The RPRD2 CID apo structure at 1.8-Å resolution was also similar to those of the RPRD1A and RPRD1B CIDs (Supplementary Fig. 1 ), thus suggesting that it might interact similarly with CTD peptides.
The influence of RPRD CID contact residues on CTD binding
To verify the interaction surface between the RPRD CIDs and CTD peptides, we mutated various CTD-interacting and evolutionarily conserved residues in the CIDs (Fig. 3a) and examined their effects on npg a r t i c l e s binding by ITC. Mutating R114 or D65 to alanine in the RPRD1A CID diminished binding to all three tested peptides (S2P, S7P and UnM), whereas N18A, Q20A and R72A mutations had little effect (Fig. 3b) .
Similarly, an RPRD1B CID R114A mutation abolished binding to both S2P and S7P CTDs, whereas Q20 and R72 mutations had little effect (Fig. 3c) . As expected, the RPRD1A R106A mutation strongly reduced binding (~27-fold) to an S2P peptide but had little effect on binding to S7P and UnM peptides (Fig. 3b) . These results confirmed the conserved CTD-recognition modes of the RPRD1A and RPRD1B CIDs in our crystal structures, in which R114 and D65 are most important for interaction independent of phosphorylation state, and R106 is important for specific interaction with an S2P CTD peptide.
To examine the effects of CID mutations on interaction with RNAPII in vivo, we immunoprecipitated extracts from HEK293 cells stably expressing wild-type and mutant RPRD1B proteins with VAP (versatile affinity purification) tags (containing 3× Flag, hexahistidine (His 6 ) and streptactin), using antibodies recognizing the Flag epitopes, total RNAPII or various RNAPII phosphoisoforms. Western blotting revealed that, consistently with the ITC results, the R114A mutation abolished RPRD1B binding to total RNAPII (N20 antibody in Fig. 3d ) and various phosphoisoforms, whereas the R72A and Q20A mutations had no such effects (Fig. 3d) . When taken together, these data revealed a molecular basis for S5P interference and an intrinsic preference of the RPRD CIDs for the S2P CTD phosphoisoform.
Dimerization of RPRDs
The RPRD1A and RPRD1B C-terminal regions (and residues 189-317 of RPRD2) are predicted to contain coiled-coil domains (Fig. 1a) previously known to mediate protein oligomerization 45 . Indeed, sizeexclusion chromatography eluted full-length RPRD1A and RPRD1B, as well as their coiled-coil domains, as apparent multimers, whereas their CIDs eluted as monomers (Supplementary Fig. 2a) . Similarly, full-length RPRD1A and RPRD1B behaved like multimers in dynamic light-scattering (DLS) analysis, whereas the three RPRD CIDs behaved like monomers (Supplementary Fig. 2b ). Because size-exclusion chromatography and DLS overestimate asymmetric protein sizes, we used analytical ultracentrifugation (AUC) to estimate molecular weights unbiased by protein geometry. The ratios of deduced molecular weights obtained from sedimentation equilibrium to the predicted monomer ones were 2.4, 2.2 and 1.0 for full-length RPRD1A, its coiled-coil domain and CID, respectively (Supplementary Table 2) . Similarly, ratios were 2.0, 1.9 and 1.0 for full-length RPRD1B, its coiled-coil domain and CID, respectively (Supplementary Table 2) .
Because RPRD1A and RPRD1B behaved similarly in the above experiments, we further verified these observations, focusing on RPRD1B. Sedimentation velocity revealed that most full-length RPRD1B and its coiled-coil domain exist as dimers (82.7% and 89.6%, respectively), but its CID was almost entirely monomeric (94.0%) (Supplementary Table 3 ). Furthermore, upon cross-linking with a relatively low concentration (30-300 µM) of suberic acid-bis-(3-sulfo-N-hydroxysuccinimide ester) (BS3), substantial amounts of intact RPRD1B and its coiled-coil domain migrated in SDS-PAGE gels at molecular masses approximately equivalent to dimers, whereas its CID migrated at the position equivalent to monomers until a higher BS3 concentration (300-3,000 µM) was used ( Supplementary Fig. 2c) . Collectively, these data demonstrated that RPRDs behave mainly as dimers with their coiled-coil domains as the dimerization modules.
To better understand the mechanism of dimerization, we obtained a 2.2-Å structure of the RPRD1B coiled-coil domain (residues L176-P301). This domain crystallized as a homodimer with a headto-tail association mode (Fig. 4a) . Each of the two polypeptides contained two major helices (α1 and α2) with the two α2 helices being extensively intertwined (Fig. 4a) . N-terminal regions (L176-A191) of the two α1 helices contacted each other in an antiparallel mode b a a r t i c l e s and were packed against the central region of the two α2 helices and located at the same side of the homodimer (Fig. 4a) . This fold potentially serves as a pad for the ipsilateral presentation of two N-terminal CIDs. Because of the high sequence identity of the RPRD1A and RPRD1B coiled-coil domains (64.3%) and their similar biochemical and biophysical behaviors, we predict that the RPRD1A coiled-coil domain would fold in the same way. Homodimerization of the RPRDs should enhance their binding to dual RPRD-binding CTD peptides. To address this issue, we used S2P peptides with either one (S2-5P CTD, in which S2P and S5P are on different CTD repeats) or two (S2-5-2P CTD) CID-binding sites in ITC experiments. The affinities of full-length RPRD1A and RPRD1B for peptides with two CID-binding sites were approximately six-fold greater than those for peptides with one binding site, whereas we observed no significant difference for their CIDs (Fig. 4b) . Again, S5P in the neighboring region had no effect on affinity (Fig. 4b) . RPRD dimer-enhanced affinities may help account for the substantial copurification of the RPRDs with RNAPII 41 .
Given the high sequence identity of the RPRD1A and RPRD1B coiled-coil domains, and the substantial reciprocal copurification of the two proteins 41 , we thought that they may form heterodimers. To test this possibility, we first asked whether coprecipitation of RPRD1A and RPRD1B requires RNAPII. When we grew cells in the presence of α-amanitin to eliminate endogenous RNAPII (ref. 46) , as confirmed by western blotting with N20 antibodies, VAP-tagged RPRD1A and RPRD1B coprecipitated with each other but not with GFP (Fig. 4c) . In addition, VAP-tagged RPRD1B R114A, a mutant that does not bind RNAPII (Fig. 3d) , also coprecipitated with RPRD1A (Fig. 4d) .
These results indicated an RNAPII-independent interaction between RPRD1A and RPRD1B. To determine whether the interaction is direct, we carried out glutathione-S-transferase (GST) pulldown experiments and found that recombinant GST-RPRD1A pulled down full-length RPRD1B and its coiled-coil domain but not its CID ( Fig. 4e and  Supplementary Fig. 3 ), a result suggesting heterodimerization via their coiled-coil domains.
RPRD1A and RPRD1B mediate RPAP2 association with RNAPII
Given that RPAP2 does not directly bind the S5P CTD 33 , we thought other factors might be required for RPAP2 binding to RNAPII. The copurification of RPRD1A and RPRD1B with RPAP2 (ref. 41) suggested that RPRDs might be such factors. To test this possibility, we first asked whether association of RPAP2 with RPRDs in vivo requires RNAPII. VAP-tagged RPRD1B coprecipitated with RPAP2 equally well after cells were grown in the presence or absence of α-amanitin (Fig. 5a) , thus indicating an RNAPII-independent interaction between RPAP2 and RPRD1B. VAP-tagged RPRD1A also coprecipitated RPAP2 after cells were grown in the presence of α-amanitin, although to a lesser extent (Fig. 5a) , a result indicating that most RPRD1A might not be associated directly with RPAP2 and would coprecipitate it only indirectly via RNAPII and RPRD1B. Next, we found that recombinant GST-RPAP2 pulled down both RPRD1A and RPRD1B (Fig. 5b) , thus suggesting a direct interaction. We also found that recombinant full-length RPRD1A and RPRD1B, but not their CIDs or coiled-coil domains, interacted weakly with recombinant RPAP2 in ITC experiments (Supplementary Table 4) . Collectively, these data demonstrated that RPRD1A and RPRD1B bind directly to RPAP2. 
To address this issue, we carried out coimmunoprecipitation with extracts from HEK293 cells depleted of an RPRD protein. Because RPRD1A and RPRD1B form heterodimers, knocking down either one seemed likely to disrupt their function. Indeed, knocking down RPRD1A by stable expression of lentiviral-encoded short hairpin RNAs (shRNAs), or by transient expression of short interfering RNAs (siRNA) (Z.N. and X.G., unpublished data), substantially reduced the RPAP2 coprecipitated by antibodies recognizing either S2P or S5P on the RNAPII CTD, whereas the amount of precipitated RNAPII remained unchanged (Fig. 5c) . Conversely, and in contrast, RPRD1A was coprecipitated by anti-S5P RNAPII CTD antibodies equally well after knockdown of GFP or RPAP2 (Fig. 5d) , thus indicating that RPRD-RNAPII association does not need RPAP2. Chromatin immunoprecipitation (ChIP) carried out in HeLa cell extracts indicated that RPAP2 occupies various promoters that we tested, but not a U2 snRNA untranscribed region, and siRNA-mediated knockdown of RPRD1A almost abolished RPAP2 association with various tested promoters, whereas RNAPII levels were reduced only by up to 50% at those promoters (Fig. 5e) . Disrupting RPAP2 recruitment by knocking down RPRD1A alone further supported the notion that RPRD1A and RPRD1B are functional as heterodimers. When taken together, these results demonstrate that RPRDs are required for RPAP2 association with RNAPII in vivo.
RPRDs stimulate CTD S5P dephosphorylation by RPAP2 in vitro
The Murphy 33 a r t i c l e s and functional RPAP2 fragment, RPAP2(1-334) 33 , with the phosphatase substrate 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP). RPAP2(1-334), but neither RPRD1A nor RPRD1B, dephosphorylated DiFMUP in a time-and dose-dependent manner (Fig. 6a) . We obtained similar results for full-length RPAP2 (G.O.H. and A.L.M., unpublished data). RPAP2 activity was not affected by addition of RPRD1A or RPRD1B but was fully or partially inhibited by the phosphatase inhibitor vanadate and several metals (Supplementary Fig. 4a-c) . We detected no measurable phosphatase activity when using the canonical phosphatase substrate p-nitrophenylphosphate (pNPP) (G.O.H. and A.L.M., unpublished data), a result indicating that RPAP2 phosphatase activity is substrate specific. To determine whether RPAP2 can dephosphorylate CTD substrates in vitro, we used an enzyme-linked immunosorbent assay (ELISA) in which the products of phosphatase reactions containing biotinylated CTD peptides were adsorbed to streptavidin-coated wells in ELISA plates. We assessed phosphorylation levels with antibodies that specifically recognize particular CTD phosphoisoforms. In agreement with previous observations 39 , we detected no measurable phosphatase activity on S5P-or S2P-containing CTD peptides in reactions with RPAP2 alone (Fig. 6b-d) .
Given that RPRDs tether RPAP2 to RNAPII (Fig. 5) , and overexpression of RPRDs decreases S5P at various promoters 41 , we hypothesized that RPRDs might stimulate RPAP2 activity on CTD substrates. Indeed, ELISA experiments showed that recombinant RPAP2 in conjunction with recombinant RPRD1A, but not its CID or coiled-coil domain, dephosphorylated S5P in a time- (Fig. 6b) and dose-dependent manner (Fig. 6c) . S2P was dephosphorylated to a much lesser extent (Fig. 6c) . We obtained similar results for RPRD1B but not for its R114A mutant that fails to bind the CTD (Fig. 6d) . RPRD1A-dependent S5 dephosphorylation by RPAP2 was also inhibited by vanadate and several metals (Supplementary Fig. 4d) , thus suggesting that similar dephosphorylation mechanisms operate on DiFMUP and CTD substrates. The CTD dephosphorylation rate was low (Fig. 6b) , probably because the RPAP2 concentration in our reactions (3 µM) was much lower than the K d of the RPAP2-RPRD interaction (447-478 µM, Supplementary Table 4) . Post-translational modifications or other factors may strengthen this interaction in vivo or, alternatively, compartmentalization in transcription factories may increase the local concentrations of RNAPII, RPRDs and RPAP2.
Interestingly, and consistently with RPRD dimerization, a CTD peptide containing two S2P CID-binding sites bracketing an S5P residue located in the intervening sequence (S2-5-2P CTD) served as a npg a r t i c l e s substrate in reactions containing RPRD1A or RPRD1B (Fig. 6c,d) , whereas S5P located outside two S2P-containing CID-binding sites (S2-2-5P CTD) did not (Fig. 6c,d ).
We then asked whether S7P CTD could also stimulate the RPRDdependent CTD phosphatase activity of RPAP2. Because S7P next to S5P in a dual RPRD CID-bound S7P CTD peptide (S77-5-77P CTD) prevented antibody recognition of S5P in ELISAs (Supplementary Fig. 4e ), we used a peptide with an unmodified S7 adjacent to S5P (S77-5-7P CTD) for the assay. RPRD1A or RPRD1B stimulated RPAP2 activity toward S5P, but not S7P (Supplementary Fig. 4f ), although to a lesser extent than for S2-5-2P CTD peptides (Fig. 6c,d ). Perhaps this was because of the lower affinities of RPRD1A and RPRD1B for the S77-5-7P CTD peptide (20.0 ± 4 µM and 12 ± 2 µM, respectively) than for the S77-5-77P CTD peptide (7.6 ± 1.5 µM and 2.7 ± 0.5 µM, respectively) or the S2-5-2P CTD peptide (4.3 ± 2.4 µM and 1.7 ± 1.3 µM, respectively).
Next, we tested whether RPAP2 is needed to dephosphorylate S5P in vivo. ChIP experiments showed that knocking down RPAP2 in HEK293 cells with two independent shRNAs increased the levels of S5P relative to RNAPII at several tested promoter regions (Supplementary Fig. 5a ), even though no obvious global change of either S5P or S2P phosphorylation was detectable by western blotting (Supplementary Fig. 5b) . Consistently with this, siRNA-mediated knockdown of RPRD1A in HeLa cells increased the S5P levels near the ACTB (β-ACTIN) promoter and other promoter regions (Supplementary Fig. 5c ). These results were in line with our previous observation that overexpression of RPRDs leads to a decrease of S5P at various promoter regions 41 .
In summary, multiple S2P-CTD and/or S7P-CTD repeats interact with the two CIDs of homo-and/or heterodimeric RPRD1A and/or RPRD1B, which in turn recruit RPAP2 to dephosphorylate the S5P specifically located in the intervening region (Fig. 7a,b) . Thus, RPRDs serve as scaffolds that recruit RPAP2 and organize the CTD into an appropriate conformation for the specific dephosphorylation of S5P by its substrate-selective phosphatase activity (Fig. 7a,b) .
DISCUSSION
We have shown that the RPRD1A and RPRD1B coiled-coil domains enable them to homo-and/or heterodimerize and present a two-CID scaffold, probably on the same side of the coiled-coil domain, for interaction with RNAPII CTD repeats (Fig. 7a,b) . The consensus CTD peptide bound in the channel of each RPRD CID is the decamer sequence PSYSPTSPSY rather than a simple CTD heptapeptide repeat (underlined). Thus, the consensus CTD sequence bound by the two CIDs in an RPRD dimer is the tetracosamer (24-mer) sequence PSY SPTSPSYSPTSPSYSPTSPSY, which contains two CID-binding sites (underlined) that bracket an intervening tetramer sequence SPTS (S5 underlined). Although RPRD1A and RPRD1B homodimers exhibit different affinities for noncanonical CTD repeats, such differences might not be significant for RPRD1A-RPRD1B heterodimers. Because RPRD CIDs bind both canonical and noncanonical CTD repeats (Table 1) , and each RPRD dimer occupies more than three heptapeptide repeats, each mammalian 52-repeat RNAPII CTD could theoretically accommodate up to 13 such structures (Fig. 7c) . Interaction of CIDs with ten rather than seven CTD amino acids probably explains why the functional unit of the CTD appears to contain two heptapeptide repeats 47 .
Dimerization of the RPRDs enhances CTD binding, an effect that could be explained by the synergistic effect of multiple CID-CTD interactions. A similar synergistic effect has been observed for binding of yeast Pcf11 and Rtt103 to S2P CTD, in which these two proteins bind cooperatively with each other to result in enhanced CID-CTD interaction 43 . Pcf11 is also a subunit of CF1A in which two other subunits, Rna14 and Rna15, form a heterotetramer that also interacts with the CTD 48 . Thus, the phenomenon of CID cooperativity in CTD recognition and transcription regulation is probably conserved between yeast and humans.
Our data indicate that RPAP2 is a substrate-selective phosphatase. In CTD peptides, the SPTS tetramer bracketed by a pair of RPRD dimer-bound S2P and/or S7P CTD repeats is likely to be the appropriate substrate for RPAP2 (Fig. 7a,b) . Therefore, a precise CTD conformation oriented by RPRD dimers presents an ideal CTD arrangement to RPAP2. We designate the CTD-RPRD dimer-RPAP2 npg a r t i c l e s complex as a 'CTDsome' (Fig. 7a,b ). This CTDsome model describes a new organization of the CTD repeats, reveals how this helps the substrate-selective RPAP2 phosphatase recognize its CTD target and precisely delineates a mechanism for regulating S5P that uniquely requires CTD-code cross-talk from S2P and S7P to S5P. During transcription initiation, TFIIH phosphorylates both S5 and S7 on the CTD [11] [12] [13] 15 . Subsequently, S7P facilitates association of p-TEFb with the CTD 49 , hence leading to phosphorylation of S2. In the transition from initiation to elongation, RPRD dimers bound to pairs of S2P and/or S7P CTD decamers would recruit RPAP2 to dephosphorylate S5P. The timing of this cascade is highly similar to that of Rtr1-dependent S5P dephosphorylation, which occurs in the transition from initiation to elongation in yeast 32 .
RPRDs are capable of associating with transcription complexes not only in promoter regions but also in gene bodies and near mRNA 3′ ends 40, 41 . This makes it likely that RPRD scaffolds could have additional roles other than S5 dephosphorylation in transcriptional regulation. Given that RPRD1B is an oncoprotein overexpressed in more than 80% of human tumors 40 , deciphering the particular activity of RPRD1B involved in tumorigenesis is an important future goal. The high-resolution crystal structure of the RPRD1B CID in complex with S2P CTD may be useful for the design and development of anticancer compounds that regulate the CTD binding activity of RPRD1B.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The crystal structures described in this paper have been deposited in the Protein Data Bank under accession codes 4FLB (RPRD2 CID), 4JXT (RPRD1A CID-S7P CTD complex), 4Q94 (RPRD1B CID-S2P CTD complex), 4Q96 (RPRD1B CIDunmodified CTD complex) and 4FLA (RPRD1B coiled-coil domain) (Supplementary Table 1 Fig. 5e and Supplementary Fig. 5c) . A 100-µl aliquot of sonicated chromatin was immunoprecipitated (IP) with 2 µg antibodies overnight at 4 °C. IP samples were centrifuged at 13,200 r.p.m., and supernatant was incubated with 10 µl of staph A at room temperature for 15 min (or 15 µl of Dynabeads at 4 °C for 1 h, Fig. 5e and Supplementary Fig. 5c ). Precipitates were washed sequentially for 3 min in 1× dialysis buffer (2 mM EDTA, 50 mM Tris-HCl, pH 8, and 0.2% sarkosyl) twice, then with IP wash buffer (1% Nonidet P-40, 100 mM Tris-HCl, pH 9, 500 mM LiCl 1% and deoxycholic acid) four times. Samples were extracted twice with 150 µl of elution buffer (1% SDS and 50 mM NaHCO 3 ) and then heated at 65 °C overnight to reverse cross-links, and DNA fragments were purified with a QIAEX II Gel Extraction kit (Qiagen, 20051) . A 4-µl aliquot from a total of 200 µl was used in qPCR with the following primers: RPRD1A promoter forward, TGCTTCTTTGACAGAGTTTCCA and reverse, TGATGCCTGGGTTACTCTCA; LEO1 promoter forward, ATACCCAGGCGAGAACAGGT and reverse, GACAGTGTCGCAAAGATTCG; MED12 forward, TCTAGGCCAAAACCGAGCTA and reverse, GATGCA AACCAGGGAAGAAG; CTR9 promoter forward, GGAGAGTCAGACG CCAGATG and reverse, GAAGCTTTTGTTGGCGTGTC; ACTB (β-ACTIN) forward, GGGCAACCGGCGGGGTCTTT and reverse, ACGCAGTTAGCGC CCAAAGG; U2 snRNA untranscribed region forward, CAGCTGTGGCTG GACAGGTTGGACC and reverse, CAGGGTTCCTGCACATTCACAGTTA. The yields of ChIP DNA were quantified with the SYBR Green kit (Applied Biosystems) with the 7300 Real Time PCR System (Applied Biosystems), or a Rotorgene RG-3000 (Corbett Research) in a 5-µl volume (or 10-µl volume, Fig. 5e and Supplementary Fig. 5c ) in duplicates. PCRs consisting of 40 cycles of 95 °C for 15 s and 55 °C for 30 s were performed. Qt values were compared with a standard curve, the copy number was calculated, the amount of DNA precipitated by an irrelevant antibody to GAL4 or IgG subtracted, and the percentage ChIP DNA relative to input chromatin calculated.
Isothermal titration calorimetry (ITC) measurements. ITC measurements were recorded at 25 °C with a VP-ITC microcalorimeter (MicroCal). Various peptides were dissolved and dialyzed into the same buffer as that of the protein. 10 µl of peptide solution or proteins (500 µM) were injected into a sample cell containing 25 µM protein in 10 mM HEPES, pH 7.5, and 150 mM NaCl. A total of 25 injections were performed with a spacing of 180 s and a reference power of 15 µcal/s. Binding isotherms were plotted and analyzed with Origin Software (MicroCal). The ITC measurements were fitted to a one-site binding model.
Dynamic light scattering (DLS)
. DLS experiments were performed with a DynaPro Titan instrument (Wyatt Technologies Corporation) equipped with a plate reader. 50 µl of 1 mg/ml proteins in buffer containing 10 mM HEPES, pH 7.5, and 150 mM NaCl were placed in 384-well optical-bottom NUNC plates. The instrument laser power was adjusted to approximately 1 × 10 6 counts/s, and data were collected with acquisition time of 10 s and averaged for ten acquisitions. Analysis of the data was performed with Dynamics software.
In vitro DiFMUP phosphatase assay. Recombinant proteins with or without the inhibitors were incubated with 10 µM 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP, Molecular Probes) at 37 °C in black, flat-bottom, polystyrol 96-well plates in 100 µl reaction buffer (50 mM 3, 3-dimethylglutaric acid, pH 6.5, and 150 mM NaCl 2 ), and fluorescence was measured every 20 min for 2 h with a SpectraMax M5 Microplate reader. The relative fluorescence was compared against a standard curve of DiFMUP to determine the amount of products produced. Recombinant GST was reconstituted in the reaction buffer and used as a negative control throughout. Initial rates were determined by plotting the amount of product produced versus time.
In vitro phosphatase enzyme-linked immunosorbent assay (ELISA). 25 pmol biotinylated CTD peptides were added into NeutriAvidin (Thermo Scientific, 31000)-coated Maxisorp plates (Thermo Scientific, 464718) overnight at 4 °C. Recombinant proteins were incubated in 30-µl reactions in buffer containing 50 mM Tris-HCl, pH 6.5, 10 mM MgCl 2 , 20 mM KCl and 5 mM DTT at 37 °C. After washing with PBS plus 0.5% Tween-20, antibodies were added and incubated at room temperature for 1 h, and this was followed by incubation with horseradish peroxidase-conjugated goat anti-mouse or mouse antirabbit secondary antibodies (Jackson Lab, cat. no. 115-035-174 and 211-032-171, respectively), the addition of TMB peroxide substrate (Thermo Scientific, 34021) and the measurement of absorbance signals at 450 nm.
Size-exclusion chromatography. Size-exclusion chromatography was carried out with a Superdex 75 HR 26/60 or Hiload16/60-Superdex 200 (GE Healthcare) column attached to an AKTA FPLC (GE Healthcare). The column was equilibrated with buffer containing10 mM HEPES, pH 7.5, 150 mM NaCl. Gel Filtration Standard (Bio-Rad, 151-1901) was used. All experiments were performed at 4 °C. Proteins were detected by absorbance measured at 280 nm.
GST pulldown. GST-and histidine-tagged proteins expressed in E. coli. were sonicated and incubated overnight at 4 °C. This was followed by pulldown with glutathione beads. The beads were then washed four times with suspension buffer (20 mM Tris, pH 7.5, 400 mM NaCl, and 5% glycerol) and subsequently eluted with elution buffer (20 mM Tris, pH 7.5, 400 mM NaCl, and 10 mM reduced glutathione). Eluted materials were resolved on SDS-PAGE gels, and proteins were detected by anti-histidine antibodies or anti-RPRD1A or anti-RPRD1B antibodies.
Protein cross-linking. Suberic acid-bis-(3-sulfo-N-hydroxysuccinimide ester) (BS3, ProteoChem) was freshly dissolved in 25 mM sodium phosphate, pH 7.4, at a concentration of 50 mM. BS3 solution was incubated with proteins in 50 µl at room temperature for 1 h, and this was followed by quenching of the unreacted BS3 with 40 mM Tris for 15 min at room temperature. Proteins were separated by Tris 4-20% SDS-PAGE gels (BioRad) and stained by the Coomassie blue reagent Instant Blue (Expedeon).
Statistical analysis.
The P values in ChIP, ELISA, ITC and DiFMUP vanadate inhibitor assays were analyzed by a two-tailed Student's t test. The data analysis in DiFMUP metal inhibitor assays was performed with GraphPad Prism 6.0 for Windows, in which the P value was determined with a one-way ANOVA Tukey's multiple comparison test.
Original images of the gels used in this study can be found in Supplementary Data Set.
